These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 3045321)
61. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Gonzatti-Haces M; Seth A; Park M; Copeland T; Oroszlan S; Vande Woude GF Proc Natl Acad Sci U S A; 1988 Jan; 85(1):21-5. PubMed ID: 3277171 [TBL] [Abstract][Full Text] [Related]
62. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Mysliwiec T; Perego R; Kruh GD Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720 [TBL] [Abstract][Full Text] [Related]
63. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879 [TBL] [Abstract][Full Text] [Related]
64. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415 [TBL] [Abstract][Full Text] [Related]
65. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Gumireddy K; Baker SJ; Cosenza SC; John P; Kang AD; Robell KA; Reddy MV; Reddy EP Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1992-7. PubMed ID: 15677719 [TBL] [Abstract][Full Text] [Related]
66. Catalytic and non-catalytic domains of the Fujinami sarcoma virus P130gag-fps protein-tyrosine kinase distinguished by the expression of v-fps polypeptides in Escherichia coli. Sadowski I; Pawson T Oncogene; 1987 May; 1(2):181-91. PubMed ID: 2449646 [TBL] [Abstract][Full Text] [Related]
67. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019 [TBL] [Abstract][Full Text] [Related]
68. Assignment of conserved amino acid residues to the ATP site in the protein kinase domain of the receptor for epidermal growth factor. Vogel S; Freist W; Hoppe J Eur J Biochem; 1986 Feb; 154(3):529-32. PubMed ID: 3004981 [TBL] [Abstract][Full Text] [Related]
69. Protein kinase inhibitors: the tyrosine-specific protein kinases. Lawrence DS; Niu J Pharmacol Ther; 1998 Feb; 77(2):81-114. PubMed ID: 9578319 [TBL] [Abstract][Full Text] [Related]
70. Approaches to isozyme-specific inhibitors. 17. Attachment of a selectivity-inducing substituent to a multisubstrate adduct. Implications for facilitated design of potent, isozyme-selective inhibitors. Kappler F; Hampton A J Med Chem; 1990 Sep; 33(9):2545-51. PubMed ID: 2391695 [TBL] [Abstract][Full Text] [Related]
72. A 10,000 member PNA-encoded peptide library for profiling tyrosine kinases. Pouchain D; Díaz-Mochón JJ; Bialy L; Bradley M ACS Chem Biol; 2007 Dec; 2(12):810-8. PubMed ID: 18154268 [TBL] [Abstract][Full Text] [Related]
73. Protein kinase inhibitors: probes for the functions of protein phosphorylation. Casnellie JE Adv Pharmacol; 1991; 22():167-205. PubMed ID: 1835643 [No Abstract] [Full Text] [Related]